A
Arlene A. Forastiere
Researcher at Johns Hopkins University
Publications - 260
Citations - 22419
Arlene A. Forastiere is an academic researcher from Johns Hopkins University. The author has contributed to research in topics: Radiation therapy & Head and neck cancer. The author has an hindex of 61, co-authored 257 publications receiving 20454 citations. Previous affiliations of Arlene A. Forastiere include Johns Hopkins University School of Medicine.
Papers
More filters
Journal ArticleDOI
Improved Survival of Patients With Human Papillomavirus–Positive Head and Neck Squamous Cell Carcinoma in a Prospective Clinical Trial
Carole Fakhry,William H. Westra,S. Li,Anthony J. Cmelak,John A. Ridge,Harlan A. Pinto,Arlene A. Forastiere,Maura L. Gillison +7 more
TL;DR: For patients with HNSCC of the oropharynx, tumor HPV status is strongly associated with therapeutic response and survival and, after adjustment for age, tumor stage, and ECOG performance status, lower risks of progression and death are found.
Journal ArticleDOI
HPV-associated head and neck cancer: a virus-related cancer epidemic
TL;DR: In this paper, the authors highlight current understanding of the epidemiology, biology, detection, and management of HPV-related oropharyngeal head and neck squamous cell carcinoma, and describe unresolved issues.
Journal ArticleDOI
Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501).
Jacques Bernier,Jay S. Cooper,Thomas F. Pajak,M. van Glabbeke,Jean Bourhis,Arlene A. Forastiere,Esat Mahmut Ozsahin,John R. Jacobs,Jacek Jassem,K. Kian Ang,J.L. Lefebvre +10 more
TL;DR: Level I evidence was established for the postoperative adjuvant treatment of patients with selected high‐risk locally advanced head and neck cancers, with the publication of the results of two trials conducted in Europe and the United States.
Journal ArticleDOI
Long-Term Results of RTOG 91-11: A Comparison of Three Nonsurgical Treatment Strategies to Preserve the Larynx in Patients With Locally Advanced Larynx Cancer
Arlene A. Forastiere,Qiang Zhang,Randal S. Weber,Moshe H. Maor,Helmuth Goepfert,Thomas F. Pajak,William H. Morrison,Bonnie S. Glisson,Andy Trotti,John A. Ridge,Wade L. Thorstad,Henry N. Wagner,John F. Ensley,Jay S. Cooper +13 more
TL;DR: These 10-year results show that induction PF followed by RT and concomitant cisplatin/RT show similar efficacy for the composite end point of LFS, and new strategies that improve organ preservation and function with less morbidity are needed.
Journal ArticleDOI
Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
TL;DR: Addition of cetuximab to cisplatin significantly improves response rate and overall survival in recurrent/metastatic squamous cell carcinoma, and there was a survival advantage for the development of rash.